Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc....
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing...
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...
Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end ...
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases,...
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the...
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational...
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science...